Background
==========

Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and it is associated with pronounced morbidity, mortality, and socio-economic burden \[[@B1]\]. Effective therapy and prevention is crucial for the control of AF-related morbidity and mortality. However, to date, medical interventions for AF are relatively limited, because the precise mechanisms of AF have not been completely elucidated. Therefore, new methods leading to further insights into the underlying mechanisms of AF and potential novel mechanism-based therapeutic strategies are required \[[@B2]\].

MicroRNAs (miRNAs) are emerging as new regulators of gene expression at the post-transcriptional level and are shedding new light on the regulatory mechanisms underlying AF \[[@B3]\]. miRNAs are small, endogenous, single-stranded, non-coding RNAs of ∼22 nucleotides that bind target sequences in the 3′-untranslated region of target genes to induce mRNA instability or to inhibit translation \[[@B4]\]. Studies have shown that miRNAs regulate key genetic functions in cardiovascular biology and play an important role in the pathogenesis of cardiac diseases including cardiac development \[[@B5]\], cardiac hypertrophy/heart failure \[[@B6]\], myocardial infarction \[[@B7]\], myocardial ischemia-reperfusion injury \[[@B8]\], and arrhythmogenesis \[[@B9]\]. Recently, there are many studies indicating that miRNAs are involved in AF through their target genes \[[@B10]-[@B13]\].

AF often occurs concomitantly with other cardiovascular diseases such as hypertension, coronary artery disease, congestive heart failure, and valvular heart disease \[[@B14]\]. AF is also prevalent in rheumatic mitral valve disease (RMVD) \[[@B15]\]. RMVD is a major cardiovascular disease in developing countries where rheumatic fever is less well controlled, and is also a major clinical risk factor for AF \[[@B16]\]. Remodeling of the right atrium (RA) and left atrium (LA) associated with AF in RMVD patients are well established \[[@B17]\]. Studies have shown that miRNAs may be involved directly or indirectly in AF by modulating atrial remodelling \[[@B18]\]. Recently, the AF-associated miRNAs were respectively found in RA \[[@B19]\] and LA \[[@B20]\] from RMVD patients.

Morphological \[[@B21]\] and electrophysiological \[[@B17]\] differences have been demonstrated between the RA and LA, which at least in part, may reflect different mechanisms involved in AF between the RA and LA \[[@B22]\]. Thus, it is not surprising that AF-associated miRNAs of the RA may differ from those of the LA. However, most studies of AF-associated miRNAs focus on the RA; and the potential difference of AF-associated miRNAs between RA and LA are still unknown.

Thus, the aim of this study was to analyze miRNA expression profiles to compare the potential differences of AF-associated miRNAs in the RA and LA from RMVD patients who were either in an sinus rhythm (SR) or AF group.

Methods
=======

Approval was obtained from the human ethics committee of the first affiliated hospital of Sun Yat-sen University. The investigation complied with the principles that govern the use of human tissues outlined in the Declaration of Helsinki. All patients gave informed consent before participating in the study.

Human tissue preparation
------------------------

Tissue samples from the right atrial appendage (RAA) and left atrial appendage (LAA) were obtained from18 RMVD patients. 8 patients were in SR group and they did not have a history of AF; 10 patients were in AF group and they had documented arrhythmia for more than six months before surgery. The tissue samples were obtained at the time of the mitral valve replacement surgery, immediately snap frozen in liquid nitrogen, and stored at −80°C until used. The diagnosis of AF was made based on medical records and 12-lead electrocardiogram (ECG) findings. Patients with SR had no history of using antiarrhythmic drugs and were screened to ensure that they had never experienced AF \[[@B23]\]. Pre-operative color Doppler echocardiography was performed routinely on the patients. Preoperative functional status was recorded according to the New York Heart Association (NYHA) classifications.

RNA isolation
-------------

Total RNA was extracted from human tissue samples (RAA and LAA) using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. The RNA quality of each sample was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA) and the sample was immediately stored at −80°C.

MiRNA microarray processing and analysis
----------------------------------------

The miRNA microarray was processed by LC Sciences (Houston, TX, USA) as described previously \[[@B20]\]. In brief, the assay utilized 2 to 5 μg total RNA sample. The total RNA was size fractionated using a YM-100 Microcon centrifugal filter (Millipore, Billerica, MA) and RNA sequences with \< 300 nt were isolated. These small RNA were then extended at 3′-end with a poly(A) tail using poly(A) polymerase, followed by ligation of an oligonucleotide tag to the poly(A) tail for later fluorescent dye staining. Hybridization was performed overnight on a μParaflo™ microfluidic chip using a micro-circulation pump (Atactic Technologies, Inc, Houston, TX). Each microfluidic chip contained detection probes and control probes. The detection probes were made in situ by photogenerated reagent (PGR) chemistry. These probes consisted of a chemically modified nucleotide coding sequence complementary to the target microRNA (all 1,921 human miRNAs listed in the Sanger's miRNAmiRBase, Release 18.0, <http://microrna.sanger.ac.uk/sequences/>) and a spacer segment of polyethylene glycol to extend the coding sequences away from the substrate. The hybridization melting temperatures were balanced by chemical modifications of the detection probes. Hybridization was performed using 100 μL of 6× SSPE buffer (0.90 M NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formamide at 34°C. Fluorescence labeling with tag specific Cy5 dye was used for after-hybridization detection. An Axon GenePix 4000B Microarray Scanner (Molecular Device, Union City, CA) was used to collect the fluorescent images, which were then digitized using Array-Pro Image Analysis software (Media Cybernetics, Bethesda, MD). Each miRNA was analyzed two times and the controls were repeated 4--16 times.

The miRNA microarray analysis was also performed at LC Sciences. The microarray data were analyzed by subtracting the background and then the signals were normalized using a locally weighed regression (LOWESS) filter as reported previously \[[@B24]\]. Detectable miRNAs were selected based on the following criteria: signal intensity higher than 3× the background standard deviation and spot CV \< 0.5 (where CV = standard deviation/signal intensity). When repeating probes were present on an array, a transcript was listed as detectable only if the signals from at least 50% of the repeating probes were above detection level. To identify miRNAs whose expression differs among the groups, statistic analysis was performed and the *P*-values of the *t*-test were also calculated. The ratio of two samples was calculated and expressed in log~2~^scale\ (balanced)^ for each miRNA. The miRNAs were then sorted according to their differential ratios.

Quantitative real-time PCR (qRT-PCR) of miRNA expression
--------------------------------------------------------

To validate the microarray results in the study, a stem-loop qRT-PCR based on SYBR Green I was performed on differentially expressed miRNAs. The primers used are listed in Additional file [1](#S1){ref-type="supplementary-material"}. Total RNA was isolated using the TRIzol Reagent (Invitrogen) as previously described. A single-stranded cDNA for a specific miRNA was generated by reverse transcription of 250 ng of total RNA using a miRNA-specific stem-looped RT primer. Briefly, a reverse transcription reaction mixture contained 250 ng of total RNA, 0.5 μl of 2 μM stem-loop RT primer, 1.0 μl of 5× RT buffer, 0.25 μl of 10 mM each dNTPs, 0.25 μl of 40 U/μlRNase inhibitor and 0.5 μl of 200 U/μl M-MLV. An Eppendorf Mastercycler® (Eppendorf, Hamburg, Germany) was used to conduct the reverse transcription reaction at the following temperature conditions: 42°C for 60 min, 70°C for 15 min and finally held at 4°C.

Following the reverse transcription reaction, qRT-PCR was performed using an ABI PRISM® 7900HT sequence-detection system (Applied Biosystems, Foster City, CA, USA) with the Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen). According to the manufacturer's instructions, the PCR reaction (a total of 20 μl) contained 0.5 μl of RT product, 10 μl of 2× SYBR Green Mix, 0.4 μl of ROX, 0.8 μl of 10 μM primer mix, and 8.3 μl of nuclease-free water. The reaction protocol was as follows: 95°C for 2 min, followed by 40 amplification cycles of 95°C for 15 s, and 60°C for 30 s.

In qRT-PCR analysis, the relative expression level for each miRNA was calculated using a comparative cycle threshold 2^-ΔΔCt^ method for three independent experiments \[[@B25]\]. RNU6B was used as an internal control for normalizing the results.

Target prediction and function analysis
---------------------------------------

We used the human miRNA information database miRFocus (<http://mirfocus.org/> Version 2.1) to predict potential human miRNA target genes. The miRFocus provides a full gene description and functional analysis for each target gene by combining the predicted target genes from other databases (TargetScan, miRanda, PicTar, MirTarget and microT). The greater the number of databases predicting that a gene would be a target, the more likely the miRNA-mRNA interaction would be relevant \[[@B26]\]. In this study, we have included genes that were predicted by two or more databases. The miRFocus program also identifies miRNA-enriched pathways, incorporating those from the Kyoto Encyclopedia of Genes and Genomes (KEGG), Biocarta, and Gene Ontology (GO) databases, using Fisher's exact test.

Statistical analyses
--------------------

All data are presented as mean ± standard deviation and analyzed by paired *t*-test. For microarray results, miRNAs with *P*-values \< 0.1 and \|log~2~^ratio^\| \> 0.5 were considered to be significantly differentially expressed, while *P* \< 0.05 was considered statistically significant for qRT-PCR analysis.

Results
=======

Clinical characteristics of the SR and AF patients
--------------------------------------------------

Tissues from both RAA and LAA were obtained from each patient.There were no significant differences in terms of age, gender or NYHA classifications between the SR and AF groups. Pre-operative color Doppler echocardiography showed that the LA size of the patients with AF was significantly greater than patients with SR as previously reported \[[@B27]\]. There were no differences in the left ventricular ejection fraction (LVEF) between the groups (Table [1](#T1){ref-type="table"}).

###### 

Clinical characteristics of the SR and AF patients

                             **SR (n = 8)**         **AF (n = 10)**
  ---------------------- ---------------------- ------------------------
  Gender (male/female)            5/3                     5/5
  Age (years)                 50.16 ± 6.88            51.42 ± 7.12
  LA size (mm)                43.31 ± 3.23           57.65 ± 5.08\*
  LVEF (%)                    61.34 ± 5.66            58.71 ± 3.81
  NYHA class              II (6/8) / III (2/8)   II (7/10) / III (3/10)

\**P* \< 0.05 (comparing to the SR patients).

miRNA expression profiles in SR-RAA, SR-LAA, AF-RAA, AF-LAA
-----------------------------------------------------------

Of the 1,898 human miRNAs analyzed, a total of 258 miRNAs were detected (in SR-RAA, SR-LAA, AF-RAA, or AF-LAA). In the SR-RAA, SR-LAA, AF-RAA, and AF-LAA groups 164, 155, 216, and 208 miRNAs were expressed, respectively (Figure [1](#F1){ref-type="fig"}A). Among these, 132 miRNAs were detected in all groups. A number of miRNAs were expressed only in one of the four groups---6 in the SR-RAA group, 2 in the SR-LAA group, 40 in the AF-RAA group, and 19 in the AF-LAA group.

![**The numbers of miRNAs detected in SR-RAA, SR-LAA, AF-RAA and AF-LAA using miRNA microarray assay. (A)** A total of 258 miRNAs were detected (in SR-RAA, SR-LAA, AF-RAA, or AF-LAA). In the SR-RAA, SR-LAA, AF-RAA, and AF-LAA groups 164, 155, 216, and 208 miRNAs were expressed, respectively. **(B)** 178 miRNAs were expressed in SR patients (SR-RAA or SR-LAA), while 250 miRNAs were expressed in AF patients (AF-RAA or AF-LAA). **(C)** 235 miRNAs were expressed in RAA tissues (SR-RAA or AF-RAA), while 213 miRNAs were expressed in LAA tissues (SR-LAA or AF-LAA).](1479-5876-12-90-1){#F1}

Among the 258 miRNAs, 178 miRNAs were expressed in SR patients (SR-RAA or SR-LAA), while 250 miRNAs were expressed in AF patients (AF-RAA or AF-LAA). AF resulted in greater expression of miRNAs than SR (Figure [1](#F1){ref-type="fig"}B). A total of 235 miRNAs were expressed in RAA tissues (SR-RAA or AF-RAA), while 213 miRNAs were expressed in LAA tissues (SR-LAA or AF-LAA). RAA tissues had a larger number of miRNAs expressed (Figure [1](#F1){ref-type="fig"}C).

For most of the detected miRNAs, the expression levels were low, which was evident by their low signal intensities (less than 500 units) during microarray analysis (Figure [2](#F2){ref-type="fig"}). Of the 164 miRNAs detected in SR-RAA tissues, 88 miRNAs emitted signals less than 500 units, while only 8 miRNAs produced signals above 10,000 units. Of the 155 miRNAs detected in SR-LAA tissues, 86 miRNAs emitted signals less than 500 units, while only 5 miRNAs produced signals above 10,000 units. Of the 216 miRNAs detected in AF-RAA tissues, 106 miRNAs emitted signals less than 500 units, while only 7 miRNAs produced signals above 10,000 units. Of the 208 miRNAs detected in AF-LAA tissues, 129 produced signals below 500 units, while only 3 produced signals above 10,000 units.

![**Signal distributions of all detected miRNAs in SR-RAA, SR-LAA, AF-RAA and AF-LAA.** The signal intensities of most of these miRNAs were low (0--500 units), with only 23 miRNAs showing intensities greater than 10000 units.](1479-5876-12-90-2){#F2}

The signal intensities of the miRNAs expressed in only one of the four groups were not high enough to consider them differentially expressed among groups, and hence were not be considered for further analysis.

miRNA expression profiles changes associated with AF in RAA tissue
------------------------------------------------------------------

The SR-RAA group expressed 164 miRNAs, while the AF-RAA group expressed 216 miRNAs. Along with the number of detectable miRNAs, the expression levels of these miRNAs were also significantly different. Statistical analysis showed that 65 of these miRNAs were significantly dysregulated between AF-RAA and SR-RAA. Among these AF-associated miRNAs, 28 were up-regulated and 37 were down-regulated (Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}A).

###### 

miRNA expression differences between AF-RAA and SR-RAA

  **miRNA**                    **SR-RAA signal**   **AF-RAA signal**   **Log**~**2**~^**(AF-RAA/SR-RAA)**^   ***P*-value**
  --------------------------- ------------------- ------------------- ------------------------------------- ---------------
  Up-regulated (n = 28\*)                                                                                   
  hsa-miR-4687-3p                     378                1654                         2.13                     3.86E-02
  hsa-miR-4485                        119                 518                         2.12                     6.98E-02
  hsa-miR-4484                        879                3609                         2.04                     5.09E-02
  hsa-miR-762                         142                 544                         1.94                     4.24E-02
  hsa-miR-3940-5p                     489                1740                         1.83                     6.45E-02
  hsa-miR-149-3p                      107                 373                         1.81                     7.71E-02
  hsa-miR-4707-5p                     371                1295                         1.80                     6.57E-02
  hsa-miR-4281                        480                1524                         1.67                     2.85E-02
  hsa-miR-574-5p                      279                 883                         1.66                     6.56E-02
  hsa-miR-1281                        229                 713                         1.64                     2.26E-02
  hsa-miR-3141                        883                2687                         1.60                     4.32E-02
  hsa-miR-4488                       1049                2915                         1.47                     7.12E-02
  hsa-miR-1973                        876                2203                         1.33                     5.07E-02
  hsa-miR-4463                        241                 587                         1.28                     5.99E-02
  hsa-miR-4505                        213                 504                         1.24                     3.66E-02
  hsa-miR-4466                       1286                3026                         1.23                     5.73E-02
  hsa-miR-940                         280                 629                         1.17                     8.74E-02
  hsa-miR-4459                       2647                5576                         1.08                     8.57E-02
  hsa-miR-2861                       1081                2265                         1.07                     4.66E-02
  hsa-miR-4534                        105                 208                         0.99                     4.21E-02
  hsa-miR-3656                       2615                5009                         0.94                     8.13E-02
  hsa-miR-4530                       2265                4225                         0.90                     4.38E-02
  hsa-miR-4443                        182                 326                         0.84                     2.88E-02
  hsa-miR-4284                        159                 276                         0.80                     5.12E-02
  hsa-miR-4508                       1836                2991                         0.70                     2.36E-02
  hsa-miR-1915-3p                    1805                2917                         0.69                     2.12E-02
  hsa-miR-4298                       1478                2314                         0.65                     8.97E-02
  hsa-miR-4497                       3651                5392                         0.56                     6.18E-02
  Down-regulated (n = 37\*)                                                                                 
  hsa-miR-451a                       2775                 97                          −4.83                    3.47E-02
  hsa-miR-29a-3p                      778                 156                         −2.32                    5.04E-02
  hsa-miR-99a-5p                      645                 162                         −1.99                    5.83E-02
  hsa-miR-25-3p                       386                 101                         −1.93                    4.99E-02
  hsa-miR-486-5p                      632                 167                         −1.92                    5.85E-02
  hsa-miR-16-5p                       683                 186                         −1.88                    2.05E-02
  hsa-miR-455-3p                      220                 61                          −1.85                    5.70E-02
  hsa-miR-222-3p                      389                 116                         −1.75                    1.34E-02
  hsa-miR-195-5p                      902                 290                         −1.64                    5.19E-02
  hsa-miR-221-3p                      252                 82                          −1.62                    1.13E-02
  hsa-miR-22-3p                       302                 104                         −1.54                    3.02E-02
  hsa-miR-331-3p                      216                 78                          −1.47                    9.03E-02
  hsa-miR-4324                       1409                 540                         −1.38                    9.86E-02
  hsa-miR-30c-5p                     2822                1107                         −1.35                    2.87E-02
  hsa-miR-378d                        171                 69                          −1.32                    8.68E-02
  hsa-miR-125a-5p                    3506                1488                         −1.24                    6.63E-02
  hsa-miR-151a-5p                     622                 267                         −1.22                    5.18E-02
  hsa-miR-143-3p                     1732                 746                         −1.22                    4.85E-02
  hsa-miR-151b                        556                 253                         −1.13                    3.69E-02
  hsa-miR-4454                       1276                 582                         −1.13                    3.42E-02
  hsa-miR-145-5p                     7284                3352                         −1.12                    8.73E-02
  hsa-miR-378a-3p                     477                 221                         −1.11                    8.70E-02
  hsa-miR-30b-5p                     1857                 869                         −1.10                    5.33E-02
  hsa-miR-26b-5p                     1342                 638                         −1.07                    5.00E-02
  hsa-miR-133b                       3912                1868                         −1.07                    9.81E-02
  hsa-miR-107                         592                 284                         −1.06                    3.95E-02
  hsa-miR-152                         293                 141                         −1.05                    7.94E-02
  hsa-miR-30a-5p                      409                 201                         −1.03                    2.72E-02
  hsa-miR-125b-5p                    7602                3820                         −0.99                    7.43E-02
  hsa-miR-4286                        243                 128                         −0.92                    8.45E-02
  hsa-miR-191-5p                     1441                 767                         −0.91                    7.19E-02
  hsa-miR-26a-5p                     9621                5219                         −0.88                    6.04E-02
  hsa-miR-21-5p                       633                 351                         −0.85                    8.92E-03
  hsa-miR-30d-5p                     1225                 692                         −0.82                    5.79E-02
  hsa-miR-5100                        458                 274                         −0.74                    8.76E-02
  hsa-miR-181a-5p                     998                 613                         −0.70                    3.23E-02
  hsa-let-7a-5p                      16804               10484                        −0.68                    7.85E-02

\*Expression levels of miRNAs are described as up-regulated or down-regulated in AF-RAA relative to those in SR-RAA.

![**Heat map showing the miRNAs significantly dysregulated in RAA and LAA tissues. (A)** Heat map showing the expression of dysregulated miRNAs in RAA tissues (AF-RAA vs SR-RAA). **(B)** Heat map showing the expression of dysregulated miRNAs in LAA tissues (AF-LAA vs SR-LAA).](1479-5876-12-90-3){#F3}

miRNA expression profiles changes associated with AF in LAA tissue
------------------------------------------------------------------

The SR-LAA group expressed 155 miRNAs, while the AF-LAA group expressed 208 miRNAs. Along with the number of detectable miRNAs, significant differences also existed in the expression levels of these miRNAs. Statistical analysis showed that 42 miRNAs were significantly dysregulated in AF-LAA relative to SR-LAA. Among these AF-associated miRNAs, 22 were up-regulated and 20 were down-regulated (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}B)

###### 

miRNA expression differences between AF-LAA and SR-LAA

  **miRNA**                    **SR-LAA signal**   **AF-LAA signal**   **Log**~**2**~^**(AF-LAA/SR-LAA)**^   ***P*-value**
  --------------------------- ------------------- ------------------- ------------------------------------- ---------------
  Up-regulated (n = 22\*)                                                                                   
  hsa-miR-3613-3p                     294                3063                         3.38                     1.07E-02
  hsa-miR-494                         296                1881                         2.67                     5.89E-02
  hsa-miR-3591-3p                     539                2069                         1.94                     7.14E-02
  hsa-miR-4485                        80                  284                         1.83                     5.03E-02
  hsa-miR-574-3p                     4478                13516                        1.59                     2.41E-02
  hsa-miR-466                        1183                3343                         1.50                     2.31E-02
  hsa-miR-4492                        334                 834                         1.32                     2.73E-02
  hsa-let-7d-3p                       146                 344                         1.23                     9.94E-02
  hsa-miR-4707-5p                     387                 857                         1.15                     2.92E-02
  hsa-miR-4534                        79                  172                         1.12                     6.66E-02
  hsa-miR-3940-5p                     397                 803                         1.02                     5.71E-02
  hsa-miR-3178                        185                 374                         1.01                     1.97E-02
  hsa-miR-15b-5p                      383                 723                         0.92                     3.04E-02
  hsa-miR-21-5p                       442                 819                         0.89                     4.66E-02
  hsa-miR-3196                       1383                2477                         0.84                     1.34E-02
  hsa-miR-1307-3p                     82                  145                         0.83                     5.28E-02
  hsa-miR-331-3p                      140                 247                         0.82                     6.46E-02
  hsa-miR-149-3p                      96                  163                         0.77                     6.79E-02
  hsa-miR-181a-5p                    1057                1613                         0.61                     8.50E-02
  hsa-miR-30a-5p                      249                 376                         0.59                     6.94E-02
  hsa-miR-1973                        745                1123                         0.59                     6.02E-02
  hsa-miR-4497                       4574                6546                         0.52                     4.68E-02
  Down-regulated (n = 20\*)                                                                                 
  hsa-miR-1                          12740               3079                         −2.05                    1.94E-02
  hsa-miR-26b-5p                      794                 198                         −2.00                    2.30E-02
  hsa-miR-4454                       1262                 488                         −1.37                    3.93E-02
  hsa-miR-361-5p                      652                 259                         −1.33                    3.53E-02
  hsa-miR-151a-5p                     694                 302                         −1.20                    3.90E-02
  hsa-miR-26a-5p                     9702                4314                         −1.17                    7.22E-03
  hsa-miR-378a-3p                     683                 307                         −1.15                    7.26E-02
  hsa-miR-5190                        311                 141                         −1.14                    9.06E-02
  hsa-miR-5100                        775                 363                         −1.10                    2.89E-02
  hsa-miR-151b                        609                 288                         −1.08                    6.25E-02
  hsa-miR-4442                        350                 169                         −1.05                    6.69E-02
  hsa-miR-2861                       2103                1141                         −0.88                    6.50E-02
  hsa-miR-143-3p                     1380                 778                         −0.83                    9.49E-02
  hsa-miR-378d                        197                 112                         −0.82                    7.07E-02
  hsa-miR-23c                         939                 583                         −0.69                    8.28E-02
  hsa-miR-195-5p                      612                 385                         −0.67                    2.21E-02
  hsa-miR-720                         952                 619                         −0.62                    4.67E-02
  hsa-miR-4281                        836                 545                         −0.62                    6.92E-02
  hsa-let-7f-5p                      10225               7040                         −0.54                    5.58E-02
  hsa-miR-23b-3p                     12468               8685                         −0.52                    7.24E-02

\*Expression levels of miRNAs are described as up-regulated or down-regulated in AF-LAA relative to those in SR-LAA.

Comparison of AF-associated miRNAs between RAA and LAA tissues
--------------------------------------------------------------

A total of 84 AF-associated miRNAs were found (either in RAA or LAA tissues): 65 AF-associated miRNAs were found in RAA tissues, while 42 AF-associated miRNAs were found in LAA tissues. Among these, 23 AF-associated miRNAs were found both in RAA and LAA, while 45 AF-associated miRNAs were found only in RAA, and 19 AF-associated miRNAs were found only in LAA (Table [4](#T4){ref-type="table"}).

###### 

Comparison of AF-associated miRNAs between RAA and LAA

                         **Number**  **AF-associated miRNAs**
  --------------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Both in RAA and LAA        23      hsa-miR-143-3p, hsa-miR-149-3p, hsa-miR-151a-5p, hsa-miR-151b, hsa-miR-181a-5p, hsa-miR-195-5p, hsa-miR-1973, hsa-miR-21-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-2861, hsa-miR-30a-5p, hsa-miR-331-3p, hsa-miR-378a-3p, hsa-miR-378d, hsa-miR-3940-5p, hsa-miR-428, hsa-miR-4454, hsa-miR-4485, hsa-miR-4497, hsa-miR-4534, hsa-miR-4707-5p, hsa-miR-5100
  Only in RAA                42      hsa-let-7a-5p, hsa-miR-107, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-1281, hsa-miR-133b, hsa-miR-145-5p, hsa-miR-152, hsa-miR-16-5p, hsa-miR-1915-3p, hsa-miR-191-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-25-3p, hsa-miR-29a-3p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-30d-5p, hsa-miR-3141, hsa-miR-3656, hsa-miR-4284, hsa-miR-4286, hsa-miR-4298, hsa-miR-4324, hsa-miR-4443, hsa-miR-4459, hsa-miR-4463, hsa-miR-4466, hsa-miR-4484, hsa-miR-4488, hsa-miR-4505, hsa-miR-4508, hsa-miR-451a, hsa-miR-4530, hsa-miR-455-3p, hsa-miR-4687-3p, hsa-miR-486-5p, hsa-miR-574-5p, hsa-miR-762, hsa-miR-940, hsa-miR-99a-5p
  Only in LAA                19      hsa-let-7d-3p, hsa-let-7f-5p, hsa-miR-1, hsa-miR-1307-3p, hsa-miR-15b-5p, hsa-miR-23b-3p, hsa-miR-23c, hsa-miR-3178, hsa-miR-3196, hsa-miR-3591-3p, hsa-miR-3613-3p, hsa-miR-361-5p, hsa-miR-4442, hsa-miR-4492, hsa-miR-466, hsa-miR-494, hsa-miR-5190, hsa-miR-574-3p, hsa-miR-720

Validation of the miRNA microarray data by qRT-PCR
--------------------------------------------------

To validate the data obtained from the miRNA microarray, qRT-PCR was performed on 12 AF-associated miRNAs. The AF-associated miRNAs were selected for further analysis using qRT-PCR based on the following criteria: at least one group (SR or AF group) had a signal intensity \>1000 units in the RAA or LAA tissues. Finally, we selected 9 AF-associated miRNAs from RAA (Figure [4](#F4){ref-type="fig"}A) and 6 AF-associated miRNAs from LAA (Figure [4](#F4){ref-type="fig"}B). Among these: 3 miRNAs (i.e. miR-26a-5p, miR-143-3p, and miR-4454) were expressed in both RAA and LAA; 6 miRNAs (i.e. miR-30c-5p, miR-125b-5p, miR-133b, miR- 145-5p, miR-451a, and miR-4484) were expressed in only RAA; and 3 miRNAs (i.e. miR-1, miR-23b-3p, and miR-494) were expressed in only LAA.

![**Comparison of signal intensities of miRNAs significantly dysregulated in RAA and LAA tissues.** The signal intensities of miRNAs expressed in the SR group (x-axis) and AF group (y-axis) were compared. The miRNAs with the higher signal intensities (\>1000 units) either on the x-axis or y-axis were labelled red. **(A)** AF-RAA vs SR-RAA. **(B)** AF-LAA vs SR-LAA.](1479-5876-12-90-4){#F4}

According to the qRT-PCR data, miR-26a-5p, miR-143-3p, miR-4454 were AF-associated miRNAs found in both RAA and LAA tissues, while miR-30c-5p, miR-125b-5p, miR-133b, miR-145-5p, miR-4484 were AF-associated miRNAs found in only RAA tissues and miR-1, miR-23b-3p were found only in LAA tissues (Figure [5](#F5){ref-type="fig"}). Our qRT-PCR data validated the results for all of these miRNAs except miR-451a and miR-494. miR-451a was an AF-associated miRNA found only in RAA in the array data (Table [4](#T4){ref-type="table"}), but was neither found in the RAA nor LAA when assayed using qRT-PCR (Figure [5](#F5){ref-type="fig"}). miR-494 was AF-associated miRNA found only in the LAA from the array data (Table [4](#T4){ref-type="table"}), but was neither found in the RAA nor LAA when assayed using qRT-PCR (Figure [5](#F5){ref-type="fig"}).

![**Validation of the miRNA microarray data using qRT-PCR.** RNU6B was used as an internal control for normalizing the results. Data are reported as mean ± standard deviation for three independent experiments. Statistically significant differences between the two groups are indicated by \**P* \< 0.05, compared with SR-RAA **(A)** or SR-LAA **(B)**.](1479-5876-12-90-5){#F5}

Comparing expression of AF-associated miRNAs in RAA and LAA tissues from RMVD patients with SR
----------------------------------------------------------------------------------------------

We identified 10 AF-associated miRNAs using the microarray and qRT-PCR techniques. These AF-associated miRNAs had different tissue distributions between the RAA and LAA (Table [4](#T4){ref-type="table"}, Figure [5](#F5){ref-type="fig"}). We wanted to know whether expressions of these miRNAs were different between the RAA and LAA tissues based on SR status. So we next compared expression levels of these miRNAs between the SR-RAA and SR-LAA groups. The expression levels of most of the AF-associated miRNAs were identical between RAA and LAA in SR patients, with the exception of miR-23b-3p and miR-125b-5p (Figure [6](#F6){ref-type="fig"}A). miR-23b-3p was more highly expressed in the SR-LAA group than in SR-RAA, and miR-125b-5p was more highly expressed in the SR-RAA group. Moreover, we compared the expression level of miR-23b-3p and miR-125b-5p among four groups (i.e. SR-RAA, SR-LAA, AF-RAA, and AF-LAA). In LAA tissues, the expression level of miR-23b-3p was down-regulated in the AF group relative to the SR group. In RAA tissues, the expression level of miR-23b-3p did not change between the SR group and AF group (Figure [6](#F6){ref-type="fig"}B). Meanwhile, a change in miR-125b-5p expression between SR and AF groups occurred only in RAA tissues, where miR-125b-5p was more highly expressed in SR group (Figure [6](#F6){ref-type="fig"}C).

![**Comparison of validated AF-associated miRNAs expression level between RAA and LAA in SR status.** Data are reported as mean ± standard deviation for three independent experiments, \**P* \< 0.05, compared with SR-RAA **(A,B,C)**; \*\**P* \< 0.05, compared with SR-LAA **(B)** or SR-RAA **(C)**.](1479-5876-12-90-6){#F6}

Prediction of putative target genes and pathways of the AF-associated miRNAs
----------------------------------------------------------------------------

To determine the probable biological function of the AF-associated miRNAs, we predicted the putative targets and pathways of 10 validated miRNAs (i.e. miR-1, miR-23b-3p, miR-26a-5p, miR-30c-5p, miR-125b-5p, miR-133b, miR-143-3p, miR-145-5p, miR-4454, and miR-4484) using the miRFocus database.

Most of these miRNAs were predicted by 5 target prediction databases except miR-4454 and miR-4484. miR-4454 cannot be predicted using 5 target prediction databases, while, miR-4484 can be predicted using 2 target prediction databases. Numerous putative target genes and pathways were identified for these miRNAs except miR-4454. Many of these predicted targets have been experimentally validated (Table [5](#T5){ref-type="table"}, Additional file [2](#S2){ref-type="supplementary-material"}).

###### 

Prediction of putative target genes and pathways of the validated miRNAs

  **miRNAs**     **target gene**   **GO term**   **KEGG pathways**   **Target prediction database**  
  ------------- ----------------- ------------- ------------------- -------------------------------- ------------------------------------------------
  miR-1                135             68               101                        9                 miRanda, MirTarget, microT, PicTar, TargetScan
  miR-23b-3p           296              8               91                         5                 miRanda, MirTarget, microT, PicTar, TargetScan
  miR-26a-5p           210              7               62                         11                miRanda, MirTarget, microT, PicTar, TargetScan
  miR-30c-5p           365              5               70                         5                 miRanda, MirTarget, microT, PicTar, TargetScan
  miR-125b-5p          80               5               35                         2                 miRanda, MirTarget, microT, PicTar, TargetScan
  miR-133b             85               3               243                        14                miRanda, MirTarget, microT, PicTar, TargetScan
  miR-143-3p           51               2               39                         24                miRanda, MirTarget, microT, PicTar, TargetScan
  miR-145-5p           127             20               82                         12                miRanda, MirTarget, microT, PicTar, TargetScan
  miR-4454              0               0                0                         0                 miRanda, MirTarget, microT, PicTar, TargetScan
  miR-4484              9               0               74                         40                MirTarget, TargetScan

The biological function and potential functional pathways of each putative gene target were classified using the GO term and KEGG pathway. Since every gene is associated with many GO terms and KEGG pathways, the significant GO term (see Additional file [3](#S3){ref-type="supplementary-material"}) and KEGG pathway (see Additional file [4](#S4){ref-type="supplementary-material"}) for each miRNA were identified using Fisher's exact test. Table [6](#T6){ref-type="table"} gives a few representative KEGG pathways for the putative target genes of the validated miRNAs as predicted by the miRFocus. The pathway analysis suggested that these miRNAs may potentially contribute to AF.

###### 

A few representative KEGG pathways for the putative target genes of the validated miRNAs

  **KEGG pathway**                                         **Target genes**                                                         **miRNAs**
  -------------------------------------------------------- ------------------------------------------------------------------------ -----------------------------------------
  TGF-beta signaling pathway                               ACVR1C, INHBB,SMAD1, SMAD3, TGFBR2,ZFYVE9                                miR-26a-5p, miR-145-5p
  MAPK signaling pathway                                   KRAS, MAP3K7, DUSP6, FLNB, PPP3CA, PRKX, RASA1, TGFBR2,MAP4K4, RAPGEF2   miR-143-3p, miR-145-5p
  mTORsignaling pathway                                    EIF4E                                                                    miR-4484
  VEGF signaling pathway                                   KRAS, SHC2                                                               miR-143-3p, miR-4484
  Calcium signaling pathway                                ADCY3                                                                    miR-4484
  Wntsignaling pathway                                     PLCB1, FRAT2, GSK3B, PPP3CB                                              miR-26a-5p
  Gap junction                                             KRAS, ADCY3                                                              miR-143-3p, miR-4484
  Regulation of actin cytoskeleton                         PFN2, ITGA6, ITGB8, KRAS                                                 miR-133b, miR-143-3p
  Hypertrophic cardiomyopathy (HCM)                        IGF1, TPM3, TPM4                                                         miR-1
  Tight junction                                           MPP5, RRAS2, VAPA, PPP2CB, KRAS                                          miR-1, miR-23b-3p, miR-133b, miR-143-3p
  Arrhythmogenic right ventricular cardiomyopathy (ARVC)   GJA1, ITGA6, SGCB, ITGB8, ACTB, ACTG1                                    miR-1, miR-30c-5p, miR-145-5p

Discussion
==========

Two recent studies investigating expression profiles of miRNA in mitral stenosis patients found the AF-associated miRNAs in RA \[[@B19]\] and LA \[[@B20]\], respectively, many of which were also found in our study. However, the studies investigated the alterations of miRNA expression profiles in relation to AF only in RA or LA tissue and they could not compare the potential differences of AF-associated miRNAs between the RA and LA. A recent study investigated changes in miRNA expression profiles in patients with valvular heart disease in relation to AF both in RA and LA tissue \[[@B28]\] and found the AF-associated miRNAs only in RA; the lack of detectable AF-associated miRNAs in LA may be partially due to lack of tissue availability; and the study also could not compare the potential differences of AF-associated miRNAs between the RA and LA. Thus, our study is the first to compare the potential differences of AF-associated miRNAs in the RA and LA from RMVD patients. We found that the development of AF in RMVD patients was associated with significant changes in miRNA expression in both RAA and LAA tissues, and these AF-associated miRNAs had different distributions in RAA and LAA. A total of 23 AF-associated miRNAs were both in RAA and LAA, while 45 AF-associated miRNAs were only in RAA, and 19 AF-associated miRNAs were only in LAA. The differential distributions of these AF-associated miRNAs may reflect different miRNAs mechanisms in AF between the RA and LA.

miRNA expression profiles are genetically programmed with temporal patterns (depending on developmental stage or disease status) \[[@B29]\]. Specific alterations in miRNA expression profiles are associated with specific disease pathophysiologies \[[@B30]\]. Our study has shown that AF status resulted in a larger number of miRNAs expressed as compared to the SR status (Figure [1](#F1){ref-type="fig"}B) and the AF-associated miRNAs were found in both RAA (Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}A) and LAA (Table [3](#T3){ref-type="table"}, Figure [3](#F3){ref-type="fig"}B) tissues from RMVD patients. Studies have shown that miRNAs may be involved directly or indirectly in AF by modulating atrial electrical remodeling (i.e. miR-1, miR-26, and miR-328) or structural remodeling (i.e. miR-30, miR-133, and mir-590). Yang et al. \[[@B31]\] reported that miR-1 overexpression slowed conduction and depolarized the cytoplasmic membrane by post-transcriptionally repressing KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2; which encodes the K^+^ channel subunit Kir2.1) and GJA1 (gap junction protein, alpha 1, 43 kDa; which encodes connexin 43), and this likely accounts at least in part for its arrhythmogenic potential. Girmatsion et al. \[[@B32]\] indicated that miR-1 levels are greatly reduced in human AF, possibly contributing to up-regulation of Kir2.1 subunits, leading to increased cardiac inward-rectifier potassium current (I~K1~)~.~ Luo et al. \[[@B13]\] identified miR-26 as a potentially important regulator of KCNJ2 gene expression and, via I~K1~, a determinant of AF susceptibility. Li et al. \[[@B12]\] reported that miR-133 and miR-30, as anti-fibrotic miRNAs \[[@B33],[@B34]\], may play an important role in the control of structural changes in chronic AF. To date, the miR-23, miR-125, miR-143, miR-145, miR-4454, and miR-4484 have not been described as participating in AF pathology. Based on the predictions of putative target genes and pathways determined using miRFocus (Table [6](#T6){ref-type="table"}), we have found that these miRNAs are potentially involved in several important biological processes and functional pathways associated with AF (e.g., TGF-beta, MAPK, VEGF, Calcium, Gap junction, mTOR, and Wnt signalling pathway, most of which have been implicated in the pathogenesis of AF). Thus, our results may implicate these miRNAs in the pathogenesis of AF.

miRNA expression profiles are also genetically programmed with certain spatial characteristics (depending on cell, tissue, or organ type) \[[@B35],[@B36]\]. For example, miR-208 and miR-499 are cardiac-specific miRNAs exclusively expressed in cardiac tissues, while miR-1 and miR-133 are muscle-specific miRNAs preferentially expressed in cardiac and skeletal muscle \[[@B37],[@B38]\]. We have found that the expression levels of most AF-associated miRNAs were identical between RAA and LAA tissues in SR patients, with exception of miR-23b-3p and miR-125b-5p (Figure [6](#F6){ref-type="fig"}). Thus, we conclude that most of the AF-associated miRNAs, except miR-23b-3p and miR-125b-5p, were not tissue dependent and the different distribution of these miRNAs in RA and LA is caused by the different mechanisms involved in AF between RA and LA. Our results have shown that miR-23b-3p was more highly expressed in the SR-LAA group than in SR-RAA and was AF-associated miRNAs only in LAA tissue, while, miR-125b-5p was more highly expressed in the SR-RAA group than in SR-LAA and was AF-associated miRNAs only in RAA tissue. miR-23b-3p and miR-125b-5p are tissue dependent and they may play a role in the progress from SR to AF as decided by the initial expression (SR status) in RAA and LAA. The different expression of miR-23b-3p and miR-125b-5p between RAA and LAA in RMVD patients with SR maybe due to RMVD, because Cooley et al. \[[@B28]\] reported that some miRNAs expression changes in RA and LA with the development of valvular heart disease. In addition, in RMVD patients, the association between LA size and AF is well established and LA dilatation is considered both a cause and consequence of AF \[[@B15]\]. Our results have shown that LA size of the patients with AF was significantly greater than patients with SR (Table [1](#T1){ref-type="table"}), thus, it is possible that the significant structural remodelling of the LA also alters the microRNA expression profiles and cause, at least in part, the different distributions of AF-associated miRNAs in the RA and LA from RMVD patients.

The main limitation of this study was the small number of patients included. This was due, in part, to the difficulty of finding RMVD patients with SR. Second, We could not conduct experiments to modulate miRNA levels in native human tissues. Hence, the evidence presented here is not a direct cause and effect relationship. Furthermore, the exact targets and pathways of AF-associated miRNAs causing AF in RMVD patients remain elusive and deserve further investigation \[[@B19]\]. Finally, the patients included in this study were a specific cohort with preserved systolic left ventricular function and little comorbidity; they were undergoing mitral valve replacement surgery. Changes identified in this population may not be representative of other cohort of populations \[[@B32]\].

Conclusions
===========

We have found the different distributions of AF-associated miRNAs in the RAA and LAA from RMVD patients. This may reflect different miRNA mechanisms involved in AF between the RA and LA. These findings may provide new insights into the underlying mechanisms of AF in RMVD patients and provide potential novel mechanism-based therapeutic strategies for AF.
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